Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL221941 | 0.85 | CA1 (0.43) | GABRA1GABRB1GABRB2 | |
| SCHEMBL16779903 | 0.83 | GABRA1 (0.35) | GABRA1GABRB1GABRB2 | |
| SCHEMBL3675026 | 0.83 | FABP4 (0.44) | GABRA1GABRB1GABRB2 | |
| SCHEMBL661595 | 0.83 | CYP3A4 (0.37) | GABRA1GABRB1GABRB2 | |
| SCHEMBL11425338 | 0.83 | GABRA1 (0.52) | GABRA1GABRB1 | |
| SCHEMBL20635011 | 0.82 | GABRA1 (0.34) | GABRA1GABRB2 | |
| SCHEMBL6866102 | 0.82 | GABRA1 (0.47) | GABRA1GABRB1GABRB2 | |
| SCHEMBL403988 | 0.80 | CYP3A4 (0.39) | GABRA1GABRB2 | |
| SCHEMBL24891310 | 0.79 | CYP3A4 (0.38) | GABRA1GABRB1GABRB2 | |
| SCHEMBL194319 | 0.79 | GABRA1 (0.35) | GABRA1GABRB1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0964849-B1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER (US) | 2003-06-04 | — | — | EP | disclosed |
| EP-1270554-A1 | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| EP-1270565-A1 | 4-Substituted furan-2-sulfonamide and its use in the preparation of sulfonyl urea derivatives | PFIZER INC. (US) | 2003-01-02 | — | — | EP | disclosed |
| US-6433009-B1 | TREATMENT OF AUTOIMMUNE, CARDIOVASCULAR, NERVOUS SYSTEM, GASTROINTESTINAL, RESPIRATORY SYSTEM, AND VIRAL DISORDERS; ANTIDIABETIC, ANTIARTHRITIC, ANTIINFLAMMATORY AND ANTIDEPRESSANT AGENTS | PFIZER INC | 2002-08-13 | — | — | US | disclosed |
| EP-1214087-A1 | COMBINATION TREATMENT WITH IL-1RA AND COMPOUNDS THAT INHIBIT IL-1 PROCESSING AND RELEASE | Pfizer Products Inc. (US) | 2002-06-19 | — | — | EP | disclosed |
| WO-2001019390-A1 | COMBINATION TREATMENT WITH IL-1RA AND DIARYL SULPHONYL UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
| US-6166064-A | Sulfonyl urea derivatives and their use in the control of interleukin-1 activity | PFIZER INC (US) | 2000-12-26 | — | — | US | disclosed |
| EP-0964849-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998032733-A1 | SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY | PFIZER INC. (US) | 1998-07-30 | — | — | WO | disclosed |
| US-4183913-A | CARBODIIMIDE AND HETEROCYCLIC QUATERNARY AMMONIUM COMPOUND | BAYER AKTIENGESELLSCHAFT (DE) | 1980-01-15 | — | — | US | disclosed |
| US-4112065-A | Compositions of bis(ortho-substituted phenyl)carbodiimides and quaternary ammonium salts and their use thereof in combatting ectoparasitic tick infestations of animals | BAYER AKTIENGESELLSCHAFT (GE) | 1978-09-05 | — | — | US | disclosed |